[ad_1]
A recent study by researchers at New York University found that the Johnson & Johnson vaccine may be less effective in combating variants of COVID-19 than vaccines made by Pfizer-BioNTech or Moderna.
The results of the study were published by bioRxiv and have been submitted to a peer-reviewed journal.
A nurse fills a syringe with the Johnson &; Johnson COVID-19 vaccine at a pop-up vaccination site in the Staten Island borough of New York City.
(PA)
According to the study, the Pfizer and Moderna mRNA-based vaccines were 94-95% effective in preventing COVID-19, while the Johnson & Johnson “adenoviral vector” had an effectiveness rate of around 67% .
The study was led by Nathaniel Landau, a virologist at the Grossman School of Medicine at New York University.
Landau told Fox News that the aim of the study “was to determine to what extent the antibodies generated by the 3 approved vaccines neutralized the variants of concern.”
CDC: DELTA VARIANT REPRESENTS 83% OF CASES IN THE UNITED STATES
“The results show that… all three vaccines produce antibodies against the variants,” Landau said. “The vaccines that have two injections (Moderna and Pfizer) produced better antibodies than J&J. All three vaccines are good. J&J could be even better if a second injection was added.”
In a statement provided to Fox News, Johnson & Johnson cited previous studies which showed that a single shot of its COVID-19 vaccine was an 85% vaccine “to protect against serious disease and provide comprehensive protection against the disease. ‘hospitalization and death’.
CLICK HERE TO GET THE FOX NEWS APP
The company said Landau’s study did not talk about the full nature of immune protection. He cited additional company data demonstrating that a single injection COVID-19 vaccine from Johnson & Johnson “generated strong and persistent activity against the rapidly spreading Delta variant and other viral variants of SARS-CoV -2 very widespread ”.
[ad_2]
Source link